Clinical Trial Update: Rituximab Treatment of Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial of rituximab for focal segmental glomerulosclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Status: WITHDRAWN